So the history in Africa has been very extensive since the 1970s and outbreaks in those countries havehappened sporadically over the last 40 years. Here in US, right, this is our first case of anyone being sick with Ebola, and there are a number of people who have actually come into the country.
Ebola KOL Interview #3
This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study
A US key opinion leader (KOL) discusses the epilepsy treatment landscape, including new market entrant Epidiolex, and provides their perspective on late-phase pipeline anti-epileptic drugs such as Fintepla.
“When people need therapy (for advanced stage Follicular Lymphoma), there’s a whole gamut. If they have relatively low volume disease, one option, which unfortunately in the community I would say is underutilized, is single-agent rituximab.”
This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression as well as unmet needs are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, Tazverik, and mosunetuzumab.
This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression, as well as unmet needs, are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, and mosunetuzumab.
This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for gastric cancer. Disease stratifications by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Opdivo, Yervoy, Keytruda, Cyramza, Herceptin, and Enhertu.
This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.
This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for head and neck cancer. Disease stratification by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key pipeline assets highlighted include Imfinzi, Bavencio, tremelimumab, and Tecentriq.
This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for head and neck cancer. Disease stratification by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key pipeline assets highlighted include Imfinzi, Bavencio, tremelimumab, and Tecentriq.
A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed drugs, and late-phase pipeline therapies for hemophilia, including alternative coagulation promoters and gene therapies. Unmet needs are also discussed. The main marketed products covered include Hemlibra, Advate, BeneFIX, and Eloctate, and key pipeline assets highlighted are valoctocogene roxaparvovec (valrox), fitusiran, and concizumab.
A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed drugs, and late-phase pipeline therapies for hemophilia, including alternative coagulation promoters and gene therapies. Unmet needs are also discussed. The main marketed products covered include Hemlibra, Advate, and BeneFIX, and key pipeline assets highlighted are valoctocogene roxaparvovec (valrox), fitusiran, and concizumab.
A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include Enhertu, tucatinib, margetuximab, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.
A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include tucatinib, margetuximab, Onzeald, SYD985, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!